In the Lab: Development of a Her2 targeted anthracycline

[Hopeful]

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_961

Hopeful

[Rich66]

Tumor microdistribution studies further suggest that differences in the localization of doxorubicin in the tumor may be responsible for the enhanced activity of MM-302 compared to free doxorubicin and PLD.
Discussion: These preclinical data suggest that MM-302 may provide in clinical practice a new opportunity to specifically deliver an anthracycline to HER2-overexpressing tumors with a potentially cleaner safety profile and improved efficacy over currently available free or liposomal doxorubicin.

................................